Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Yasuhiro Onaka Tapped for Takeda’s Japan Sales Head
September 22, 2017
- CSL Ramping Up Investment for New Product Development, 11% R&D-to-Sales Ratio “Appropriate”: CEO
September 22, 2017
- Japan Oncology Market to Grow Annual 6-9% through 2021: IMS
September 21, 2017
- Opdivo Approved for Non-Squamous NSCLC in Taiwan
September 21, 2017
- Intuniv Hits Primary Endpoint in Adult ADHD: Shionogi/Shire
September 21, 2017
- Taiho Gets Option for Arcus’ Immuno-Oncology Portfolio in Japan, Asia
September 21, 2017
- hsCRP Levels Will Be Cardiovascular Risk Predictor: Takeda’s Post-Hoc Analysis from EXAMINE Study
September 21, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in HBV Carriers Too: PIII Sub-Analysis
September 20, 2017
- Opdivo Gets Label Expansion for Melanoma in South Korea
September 20, 2017
- NCC, Top 3 Japan Makers Form Immunotherapy Consortium with Eye on Alternative to PD-1 Inhibitors
September 20, 2017
- Armed with Japanese Data, Nichi-Iko Confident of Besting Nippon Kayaku in Remicade Biosimilar Race
September 19, 2017
- Daiichi Sankyo Links Up with MD Anderson on AML Therapies
September 19, 2017
- Aptiom Gets FDA Pediatric Nod for Partial-Onset Seizures
September 19, 2017
- Xtandi Delivers Strong Data for Non-Metastatic CRPC in a Boon for Label Expansion Overseas: Astellas
September 15, 2017
- Pralia Jumps in July GP Recollection Ranking on Indication Addition: Anterio
September 15, 2017
- Chugai’s On-the-Spot ADR Info Provisioning Tools Well Received by Physicians, Spreading to Other Makers
September 15, 2017
- Shionogi to File Sakigake-Designated Flu Drug by Year-End Based on PIII Results
September 15, 2017
- NeuroDerm Shareholders OK Acquisition by Mitsubishi Tanabe
September 14, 2017
- FDA Accepts sNDA for Mirabegron Combo Therapy: Astellas
September 14, 2017
- With Canalia Debut as Catalyst, Mitsubishi Tanabe Set to Maximize 3 Diabetes Meds
September 13, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…